A Phase 2 interventional study of Pemvidutide and Placebo in Alcohol-associated Liver Disease, sponsored by Altimmune, Inc.. Active, not recruiting at 37 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Altimmune, Inc. · Phase 2, Interventional, and Treatment
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD.
Exclusion Criteria:
Drug: Pemvidutide
Other: Placebo
Pemvidutide 2.4 mg SC Injection
Placebo SC Injection
Relative (%) reduction in liver stiffness by VCTE compared to baseline
Time frame: Week 48 and 24
Absolute reduction in liver stiffness by vibration controlled transient elastography (VCTE)
Time frame: Week 48 and 24
Absolute reduction in the Enhanced Liver Fibrosis (ELF) compared to baseline
Time frame: Week 48 and 24
Plan to share: Yes — It is anticipated that the results of this study will be presented at scientific meetings and/or published in a peer reviewed scientific or medical journal. A Publications Committee, comprised of the Investigators participating in the study and representatives from the Sponsor, as appropriate, will be formed to oversee the publication of the study results, which will reflect the experience of all participating study centers. Subsequently, individual Investigators may publish results from the study in compliance with their agreement with the Sponsor.
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Altimmune, Inc.